Interventions. Copies: This document is available on the World Wide Web sites of the
American College of Cardiology (www. cardiosource. org), the American Heart Association …

Context Clopidogrel pretreatment is recommended for patients with acute coronary
syndromes (ACS) and stable coronary artery disease who are scheduled for percutaneous …

The recommendations listed in this CPG are, whenever possible, evidence based. An
extensive evidence review was conducted through October 2012, and other selected …

The recommendations listed in this CPG are, whenever possible, evidence based. An
extensive evidence review was conducted through October 2012, and other selected …

Background—Fractional flow reserve (FFR) is well established for patients undergoing
percutaneous coronary intervention, yet little is known about candidates for coronary artery …

Objective To investigate the effect of pretreatment with P2Y 12 receptor inhibitors compared
with no pretreatment on efficacy and safety of treatment of non-ST elevation acute coronary …

Objectives: The purpose of this study was to compare 600-and 300-mg clopidogrel loading
doses in patients with ST-segment elevation myocardial infarction (STEMI). Background …

This manuscript reviews the studies performed with ALX-0081 (INN: caplacizumab), a
Nanobody targeting von Willebrand factor, in the context of current antithrombotic therapy in …

Lymphocyte G protein–coupled receptor kinase 2 (GRK2) levels are increased in patients
with chronic heart failure, and in this condition, they correlate with cardiac function. The aim …

Abstract Purpose of Review Coronary artery no-reflow phenomenon is an incidental
outcome of percutaneous coronary intervention in patients presenting with acute myocardial …